Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tongrentang CoSHSE:600085 -0.41%81 Debt-to-Equity is 0.25 as of Mar. 2026, which is 4% above its 10-year median of 0.24. GuruFocus rates SHSE:600085 with a GF Score™ of 81/100 and a GF Value™ of ¥35.95 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Beijing Tongrentang Co ranks better than 54.13% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Beijing Tongrentang Co's Debt-to-Equity or its related term are showing as below:
SHSE:600085'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.24 Max: 0.39
Current: 0.25
During the past 13 years, the highest Debt-to-Equity Ratio of Beijing Tongrentang Co was 0.39. The lowest was 0.05. And the median was 0.24.
SHSE:600085's Debt-to-Equity is ranked better than 54.13% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs SHSE:600085: 0.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Beijing Tongrentang Co Debt-to-Equity Related Terms
Beijing Tongrentang Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Beijing Tongrentang Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tongrentang Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tongrentang Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Tongrentang Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Beijing Tongrentang Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tongrentang Co (SHSE:600085) has a Debt-to-Equity of 0.25 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Beijing Tongrentang Co and its competitors. This is near median its historical median of 0.24. Over the past decade, Beijing Tongrentang Co's Debt-to-Equity has ranged from 0.05 to 0.39. According to the industry distribution chart, Beijing Tongrentang Co ranks #372 out of 811 companies in the Drug Manufacturers industry, placing it in the top 45.9%.
Is Beijing Tongrentang Co's Debt-to-Equity too high?
Beijing Tongrentang Co's current Debt-to-Equity of 0.25 is near median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.39. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Beijing Tongrentang Co's value of 0.25 is 7.4% below this industry median. Based on the distribution chart, Beijing Tongrentang Co ranks #372 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beijing Tongrentang Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tongrentang Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tongrentang Co ranks #372 out of 811 companies for Debt-to-Equity. This puts Beijing Tongrentang Co in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Beijing Tongrentang Co's value of 0.25 is 7.4% below this benchmark. Historically, Beijing Tongrentang Co's own Debt-to-Equity has ranged from 0.05 to 0.39 over the past decade. While the company's 10-year median is 0.24 vs. the industry median of 0.27, Beijing Tongrentang Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tongrentang Co's current Debt-to-Equity of 0.25 is 7.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Beijing Tongrentang Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tongrentang Co's current Debt-to-Equity is 0.25, which is near median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tongrentang Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tongrentang Co (SHSE:600085) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥35.95, compared to a current price of ¥24.35 — trading 32.3% below its estimated fair value. The current Debt-to-Equity is 0.25, which is near median its 10-year median of 0.24 and 7.4% below the Drug Manufacturers industry median of 0.27. Beijing Tongrentang Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Beijing Tongrentang Co (SHSE:600085), the current Debt-to-Equity is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tongrentang Co (SHSE:600085) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tongrentang Co stock appears to be undervalued.
The current stock price of ¥24.35 is trading 32.3% below its estimated GF Value™ of ¥35.95.
GuruFocus considers Beijing Tongrentang Co to be Significantly Undervalued.
Key valuation signals for SHSE:600085:
Debt-to-Equity: 0.25 (near median its 10-year median of 0.24)
GF Value™: ¥35.95 vs. price of ¥24.35 (32.3% below fair value)
Industry Position: 7.4% below the Drug Manufacturers median (#372 of 811)
No single metric tells the full story. See the SHSE:600085 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. The company's main products consist of Liuwei Dihuang series, Tongren Dahuoluo series, Tongren Niuhuang Qingxin series, Angong Niuhuang series, and Donkey-hide gelatin series. It distributes its products under the brand of Tongrentang.
81GF Score
Get the complete analysis for SHSE:600085
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600085 has been successfully added to your 
